Fortress Biotech (FBIO) Stock Price, News & Analysis

Company Overview

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Key Stats

• Today's Range: $1.85 to $2.05
• 50-Day Range: $1.65 to $2.13
• 52-Week Range: $1.33 to $2.89
• Volume: 631,248 shs
• Average Volume: 413,142 shs
• Market Capitalization: $56.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Fortress Biotech Stock Analysis - MarketRank™

Fortress Biotech scored higher than 42% of companies evaluated by MarketBeat, and ranked 615th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fortress Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortress Biotech is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortress Biotech is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.57% of the float of Fortress Biotech has been sold short.

Short Interest Ratio / Days to Cover

Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortress Biotech does not currently pay a dividend.

Dividend Growth

Fortress Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.57% of the float of Fortress Biotech has been sold short.

Short Interest Ratio / Days to Cover

Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FBIO Stock Analysis - Frequently Asked Questions

How have FBIO shares performed this year?

Fortress Biotech's stock was trading at $2.03 at the start of the year. Since then, FBIO stock has decreased by 5.9% and is now trading at $1.91.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) released its quarterly earnings data on Monday, March, 31st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.53. The biopharmaceutical company had revenue of $15.12 million for the quarter, compared to the consensus estimate of $16.30 million. Fortress Biotech had a negative net margin of 71.24% and a negative trailing twelve-month return on equity of 4,712.53%.
Read the conference call transcript.

When did Fortress Biotech's stock split?

Fortress Biotech's stock reverse split on Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

• Last Earnings: 3/31/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FBIO
• CIK: 1429260
• Web: www.fortressbiotech.com
• Phone: (781) 652-4500
• Fax: 781-652-4545
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $26.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +999.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46 million
• Net Margins: -71.24%
• Pretax Margin: -183.81%
• Return on Equity: -4,712.53%
• Return on Assets: -27.67%

Debt

• Debt-to-Equity Ratio: 1.74
• Current Ratio: 1.72
• Quick Ratio: 1.55

Sales & Book Value

• Annual Sales: $57.67 million
• Price / Sales: 0.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -31.83

Miscellaneous

• Outstanding Shares: 29,570,000
• Free Float: 21,320,000
• Market Cap: $56.48 million
• Optionable: Optionable
• Beta: 1.75